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for CV event reduction and our consequent conclu-
sions suggesting that the guidelines might lead to
signiﬁcant decreases in nonstatin use were consistent
with both the most current evidence at the time and
the guidelines (2).
We appreciate the added clariﬁcation provided by
the guideline authors, and note that their stated
preference for drugs proven to reduce CV events is
especially germane in the wake of the recently
released IMPROVE-IT (IMProved Reduction of Out-
comes: Vytorin Efﬁcacy International Trial) trial,
which demonstrated CV event reduction with ezeti-
mibe (3). This new information, available after the
release of both the 2013 guidelines and our paper, will
have implications for cholesterol management, and
we are currently exploring those in a new analysis of
PINNACLE (Practice Innovation and Clinical Excel-
lence) data.
We also recognize that the guidelines recom-
mended low-density lipoprotein cholesterol (LDL-C)
testing to assess appropriateness of statin response
and medication adherence. However, our paper did
not suggest that no LDL-C testing should occur
under the new guidelines, but rather that “the
new guidelines did not recommend treatment to
target LDL-C lipid levels, thus rendering repeated on-
treatment testing unnecessary” (italics our own) (2).
Under prior guidelines, repeated LDL-C testing to
determine whether a particular LDL-C target was
achieved took place with regularity, a phenomenon
that we demonstrated in our analysis and almost
certainly under-reported, given the frequency with
which LDL-C levels are checked by primary care pro-
viders (who were not included in our analysis).
Thus, our conclusion that “the cost and inconve-
nience of repeated LDL-C testing to titrate statin
medication to speciﬁc LDL-C targets would be
reduced” is consistent with the guidelines (2).
We appreciate the added clariﬁcation provided by
the guideline authors, and feel that it helps further
provide guidance to clinicians seeking to optimize
cholesterol management, and its attendant effects on
CV event reduction, for their patients.*Thomas M. Maddox, MD, MSc
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Beta-Blocker Variability
in Treatment of
Long QT SyndromeWhat Is the Confounder?We read with great interest the observational study
of patients with long QT syndrome (LQTS) by Abu-
Zeitone et al. (1) published in a recent issue of the
Journal. The key points noted by the authors
include equal efﬁcacy of 4 beta-blockers in the
general LQTS population in reducing the risk of ﬁrst
cardiac event; however, in patients with LQT2,
nadolol appeared to be the only one with signiﬁcant
risk reduction. In the high-risk patients with cardiac
events while on beta-blocker therapy, propranolol
was found to be the least effective (1). This study
was conducted in the background of studies impli-
cating propranolol as having a higher propensity to
block wild-type hERG (human ether-a-go-go related
gene) channel, which is involved in the pathogen-
esis of LQT2 (2); and differed from a recent study
showing no difference in the efﬁcacy of different
beta-blockers in preventing cardiac events in a
smaller sample of LQTS patients (3).
In the existing literature on beta-blockers spanning
more than half a century, there has been no major
study demonstrating a difference in efﬁcacy of beta-
blockers in heart rate reduction. Hence, we believe
that measuring heart rate pre- and post-use of beta-
blockers can be an effective surrogate marker of
appropriate dosing and compliance. The authors do
mention in their study limitations that registry data-
base provides reasonably reliable information about
patient compliance; however, no mention has been
made about the heart rate response on the different
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2054study groups, which could provide valuable insight.
This fact assumes a special importance in the light of
predominant tachycardia in the patient cohort on
propranolol (based on signiﬁcantly lower RR interval
duration) (1) keeping in consideration that propran-
olol works best in a 3-times-a-day/4-times-a-day
dosing pattern (with exception of long-acting for-
mulations), leading to an inherent compliance pitfall.
Nadolol, on the other hand, typically requires a
once-daily dosing, which may result in improved
compliance and a better heart rate control, and, thus,
improved efﬁcacy.
We also noted that the authors, though meticu-
lous in their description of study methods, have not
mentioned the method used to measure the QT in-
terval. It is a well-documented fact that QRS dura-
tion has an incremental beneﬁt in detection of
ventricular tachycardia when combined with QT in-
terval length (4), and novel methods of measuring
ventricular repolarization such as root mean square
electrocardiography have been described as being
better than traditional methods (5). Although the
population studied by Abu-Zeitone et al. (1) is pre-
dominantly of young age, and wide QRS may be a
rarity, it would be a useful addition to the data
analysis if not already incorporated.*Lovely Chhabra, MD
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